Table 3.
Phase 1 trials third generation tyrosine kinase inhibitors (TKI’s) – axitinib and tivozanib.
| TKI | Axitinib (Rugo, 2005) | Tivozanib (Eskens et al., 2011) |
|---|---|---|
| Number patients | 36 | 41 |
| Dose levels (mg) | Six: 10–30, 20, 2.0, 5.0, 15, 5.0 | Three: 1.0, 1.5, 2.0 |
| Schedule | Continuous (daily, BID) | Intermittent (4/2 week schedule) |
| Median age (range) | 57 (41–76) years | 56 (28–73) years |
| TUMOR TYPES | ||
| CR Ca | 0 | 10 |
| Breast | 13 | 0 |
| RCC | 6 | 9 |
| Other | 17 | 22 |
| Maximum tolerated dose | 5.0 mg BID daily | 1.5 mg daily day 1–28 |
| Clinical responses: PR stable disease | 3 (2 RCC patients) NS | 1 (RCC patient) 55% |
BID, twice daily; mg, milligram; RCC, renal cell carcinoma; CR Ca, colorectal cancer; PR, partial response; NS, not stated.